mild to moderate Balanced News

NASDAQ:FREQ Investor Notice: Investigation over Possible Securities Laws Violations by Frequency Therapeutics, Inc.

crime, law and justice

San Diego, CA -- (SBWIRE) -- 04/13/2021 -- An investigation was announced concerning potential securities laws violations by Frequency Therapeutics, Inc. in connection with certain financial statements. Investors who purchased shares of Frequency Therapeutics, Inc. (NASDAQ: FREQ), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Frequency Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made. Woburn, MA based Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. On or around October 2, 2019, Frequency Therapeutics, Inc conducted its initial public offering ("IPO"), selling 6,000,000 shares of common stock priced at $14.00 per share. On March 23, 2021, Frequency announced the topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). Frequency Therapeutics, Inc disclosed that "[t]he interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo." Shares of Frequency Therapeutics, Inc. (NASDAQ: FREQ) declined to as low as $7.34 per share on March 30, 2021. Those who purchased shares of Frequency Therapeutics, Inc. (NASDAQ: FREQ) have certain options and should contact the Shareholders Foundation. Contact: Shareholders Foundation, Inc. Michael Daniels 3111 Camino Del Rio North - Suite 423 92108 San Diego Phone: +1-(858)-779-1554 Fax: +1-(858)-605-5739 [email protected] About Shareholders Foundation, Inc. The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research ...     Apr 13, 2021

CytoDyn's COVID-19 Long-Hauler's Trial Closed as Enrollment Exceeds Goals Other OTC:CYDY


(MENAFN - GlobeNewsWire - Nasdaq) VANCOUVER, Washington, April 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , ('CytoDyn' or the 'Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today its COVID-19 long-haulers study ('CD15') is now fully enrolled. Enrollment was faster than expected because of the high number of patients wanting to participate, which now includes 56 patients in the trial. This is a multicenter Phase 2, two-arm, randomized, double blind, placebo-controlled study to evaluate the safety and efficacy of Vyrologix™ (leronlimab) in the treatment of patients with prolonged COVID-19 symptoms, a condition now known as Post-Acute COVID Syndrome (PACS). Patients will be given eight (8) weekly doses of Vyrologix™ or placebo. The final treatment for the last enrolled patient will be in early June with results expected in July. Chris Recknor, M.D., CytoDyn's Chief Operating Officer and Head of Clinical Development, said, 'These patients have been suffering from COVID-19 symptoms for more than 12 weeks, many for more than 6 months. After reviewing the results from our earlier CD10 trial involving patients with mild-to-moderate COVID-19, we recognized Vyrologix may be a solution to PACS and have since developed a better understanding of the mechanism of action and how Vyrologix works in PACS. We believe CytoDyn is now well positioned to potentially be the first to offer an effective treatment for this condition where no other therapy is currently available.' Scott Kelly, M.D., Chief Medical Officer and Head of CytoDyn's Business Development, added, 'PACS is rapidly evolving into a global health emergency. At the current rate of COVID-19 infections, global cases are expected to exceed 200 million by the end of 2021. It is estimated 10-30% of those infected will have persistent symptoms, leaving 20 to 60 million patients without effective treatmen...     Apr 09, 2021